HEALTH CATALYST, INC. (HCAT): Price and Financial Metrics


HEALTH CATALYST, INC. (HCAT): $13.94

0.23 (+1.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HCAT POWR Grades


  • HCAT scores best on the Growth dimension, with a Growth rank ahead of 78.04% of US stocks.
  • HCAT's strongest trending metric is Value; it's been moving up over the last 179 days.
  • HCAT's current lowest rank is in the Quality metric (where it is better than 10.8% of US stocks).

HCAT Stock Summary

  • Health Catalyst Inc's stock had its IPO on July 25, 2019, making it an older stock than merely 7.54% of US equities in our set.
  • The volatility of Health Catalyst Inc's share price is greater than that of 82.73% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HCAT comes in at -18.54% -- higher than that of only 19.02% of stocks in our set.
  • Stocks that are quantitatively similar to HCAT, based on their financial statements, market capitalization, and price volatility, are ZUO, PLAN, RNG, STXS, and BMRA.
  • HCAT's SEC filings can be seen here. And to visit Health Catalyst Inc's official web site, go to www.healthcatalyst.com.

HCAT Valuation Summary

  • HCAT's price/sales ratio is 11.7; this is 114.68% higher than that of the median Technology stock.
  • Over the past 26 months, HCAT's price/sales ratio has gone up 2.
  • Over the past 26 months, HCAT's price/earnings ratio has gone down 13.8.

Below are key valuation metrics over time for HCAT.

Stock Date P/S P/B P/E EV/EBIT
HCAT 2021-09-01 11.7 9.1 -18.7 -21.1
HCAT 2021-08-31 11.8 9.2 -18.9 -21.3
HCAT 2021-08-30 11.4 9.0 -18.4 -20.7
HCAT 2021-08-27 11.6 9.0 -18.5 -20.9
HCAT 2021-08-26 11.0 8.6 -17.6 -19.9
HCAT 2021-08-25 11.2 8.8 -18.0 -20.3

HCAT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HCAT has a Quality Grade of D, ranking ahead of 6.31% of graded US stocks.
  • HCAT's asset turnover comes in at 0.378 -- ranking 389th of 561 Business Services stocks.
  • 500 - Internal server error

The table below shows HCAT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.378 0.499 -0.456
2021-03-31 0.365 0.492 -0.321
2020-12-31 0.393 0.481 -0.299
2020-09-30 0.435 0.479 -0.249
2020-06-30 0.490 0.489 -0.269
2020-03-31 0.616 0.502 -0.314

HCAT Price Target

For more insight on analysts targets of HCAT, see our HCAT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $66.00 Average Broker Recommendation 1.23 (Strong Buy)

HCAT Stock Price Chart Interactive Chart >

Price chart for HCAT

HCAT Price/Volume Stats

Current price $13.94 52-week high $59.50
Prev. close $13.71 52-week low $12.33
Day low $13.46 Volume 910,788
Day high $14.10 Avg. volume 765,768
50-day MA $20.32 Dividend yield N/A
200-day MA $36.47 Market Cap 755.34M

HEALTH CATALYST, INC. (HCAT) Company Bio


Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services. The company is headquartered in Salt Lake City, Utah.


HCAT Latest News Stream


Event/Time News Detail
Loading, please wait...

HCAT Latest Social Stream


Loading social stream, please wait...

View Full HCAT Social Stream

Latest HCAT News From Around the Web

Below are the latest news stories about Health Catalyst Inc that investors may wish to consider to help them evaluate HCAT as an investment opportunity.

Goldman Sachs Sees Over 50% Gains in These 3 Beaten-Down Stocks

In a recent note, Goldman Sachs chief global equity strategist Peter Oppenheimer points out that markets are going to normalize again, and soon – but with some differences over the recent past. Oppenheimer notes that mega-cap tech stocks have seen outsized gains, and that in much of the economy, we are seeing an evolution of everything into ‘tech companies.’ There’s no denying that digital tech and wireless networking are changing the ways that we do business, across the board. But while the tech mega-caps for the most part have propped up the markets for the past year, many other stocks have taken sound beatings.

Michael Marcus on TipRanks | February 25, 2022

Temple University Health System Selects Health Catalyst's Data Platform to Help Strengthen Financial Performance and Optimize Value-Based Care

Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced an engagement with Temple University Health System, a major Philadelphia-based academic health system recognized for its work driving medical advances through clinical innovation, pioneering research and world-class education.

Yahoo | February 23, 2022

Health Catalyst Announces Intent to Acquire KPI Ninja

Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire KPI Ninja, a Lincoln, Nebraska-based provider of interoperability solutions and population health analytics.

Yahoo | February 22, 2022

10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 16, 2022

Health Catalyst to Announce Fourth Quarter and Full Year 2021 Operating Results and Host Conference Call on Tuesday, March 1, 2022

SALT LAKE CITY, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2021 operating results on Tuesday, March 1, 2022, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing (8

Yahoo | February 15, 2022

Read More 'HCAT' Stories Here

HCAT Price Returns

1-mo -29.42%
3-mo -48.73%
6-mo -68.04%
1-year -74.05%
3-year N/A
5-year N/A
YTD -64.82%
2021 -8.98%
2020 25.45%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7347 seconds.